Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods – 8 September 2023

Overview

The Therapeutic Goods Act 1989 was enacted to provide a framework for regulating therapeutic goods in Australia, ensuring that these products are of acceptable quality, safety, and efficacy. This legislation was introduced to address the need for a comprehensive regulatory system governing the manufacture, importation, supply, and advertising of therapeutic goods, thereby protecting public health. Enacted by the Commonwealth Parliament, the Act aims to ensure that therapeutic goods available in Australia meet necessary standards, which is crucial in maintaining the integrity and safety of the healthcare system. The policy objective of the Act is to safeguard public health by controlling the quality and safety of therapeutic goods through rigorous regulatory measures. This includes the ability to revoke manufacturing licenses, as demonstrated by the recent revocation of several licenses at the request of the manufacturers, highlighting the flexibility and responsiveness of the regulatory framework to industry dynamics and compliance standards.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration under the Commonwealth of Australia's Department of Health and Aged Care, applies to entities involved in the manufacturing, supply, and advertising of therapeutic goods within Australia. The Act ensures that these goods meet safety, quality, and efficacy standards to protect public health. The geographic reach of the Act is national, applying across all states and territories of Australia. The Act imposes obligations on manufacturers, importers, and suppliers of therapeutic goods, including the requirement to hold an appropriate licence for manufacturing activities. The revocation of a manufacturer's licence, as evidenced by the recent notification published on 8 September 2023, underscores the Act's regulatory oversight. This revocation can occur either at the initiative of the Therapeutic Goods Administration or at the request of the manufacturer, as seen in the cases of GlaxoSmithKline Australia Pty Ltd, Arovilla Therapeutics Ltd, Lavida Pharmaceuticals, Fresenius Kabi Australia Pty Ltd, and WA Hospitals Central Pharmaceutical Manufacturing Facility T/A AUSPMAN. The Act also allows for the extension and specification of its application through subordinate instruments, which may further detail licensing requirements, penalties for non-compliance, and other regulatory measures.

Key Provisions

Under Section 41 of the Therapeutic Goods Act 1989, the Secretary has the authority to revoke a Licence to Manufacture Therapeutic Goods. This authority is exercised through a written notice, as evidenced by the revocation of the licences held by several pharmaceutical companies, including GlaxoSmithKline Australia Pty Ltd, Arovella Therapeutics Ltd, Lavida Pharmaceuticals, Fresenius Kabi Australia Pty Ltd, and WA Hospitals Central Pharmaceutical Manufacturing Facility T/A AUSPMAN. These revocations were conducted at the request of the manufacturers themselves, as indicated in the notice issued by Katherine Clark, the Delegate of the Secretary of the Department of Health and Aged Care, Therapeutic Goods Administration. The Act imposes specific obligations on the parties to whom these licences were granted. These obligations include maintaining high standards of manufacturing quality, adhering to Good Manufacturing Practices (GMP), and ensuring that all therapeutic goods produced meet the safety, quality, and efficacy standards set out by the Therapeutic Goods Administration (TGA). Failure to comply with these obligations could lead to serious consequences, including the revocation of the licence to manufacture therapeutic goods. Section 41(1)(d) of the Act provides for the revocation of licences to manufacture therapeutic goods under certain circumstances. The primary consequence of a breach of the obligations outlined in the Act is the revocation of the licence to manufacture these goods. This revocation means that the affected companies lose their authority to produce and supply therapeutic goods within Australia. Additionally, any further breaches of the Act's provisions can lead to more severe penalties, including fines and potential legal action. The exact penalties for non-compliance with the Act are not specified in the notice but can be found in other sections of the Therapeutic Goods Act 1989, which may include substantial fines and imprisonment for serious or repeated breaches.